Caladrius

CLBS NASDAQ
2.960
-0.050
-1.66%
Closed 16:00 05/24 EDT
Open
3.020
Prev Close
3.010
High
3.020
Low
2.950
Volume
2.94K
Avg Vol (3M)
30.24K
52 Week High
11.65
52 Week Low
2.770
% Turnover
0.03%
Market Cap
30.73M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
MORE >

Recently

Name
Price
%Change